Страница 1 от 341 резултата
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2010/008944, filed Dec. 14, 2010, which claims benefit of Korean Patent Application No. 10-2010-0004901, filed Jan. 19, 2010.
FIELD OF THE
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of PCT International Application PCT/KR2011/010161, filed Dec. 27, 2011, which claims priority from Korean Patent Application 10-2011-0010585, filed Feb. 7, 2011.
TECHNICAL FIELD
The
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. national stage filing under 35 U.S.C. .sctn.371 of international application PCT/KR2009/007905, filed Dec. 29, 2009, which claims benefit of Korean Patent Application 10-2009-0022937, filed Mar. 18, 2009.
TECHNICAL FIELD
The
BACKGROUND INFORMATION
An estimated 1.1 billion adults worldwide are overweight or obese, one hundred thirty million of whom are adults in the United States. See, Haslam, D., Sattar, N., & Lean, M. (2006). Obesity--time to wake up. Bmj, 333(7569), 640-642; Flegal, K. M., Carroll, M. D., Ogden,
The present invention relates to pyrrolidinone derivatives of the formula I
##STR00001##
in which R.sup.1a, R.sup.1b, R.sup.1c, R.sup.2a, R.sup.2b, R.sup.2c, X, Y.sup.1 and Y.sup.2 are defined as indicated below. The pyrrolidinone derivatives I are GPR119 modulators and useful for the prevention
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims priority benefit to EP Application No. 17305189.7, filed Feb. 21, 2017, the disclosure of which is herein incorporated by reference in its entirety.
DETAILED DESCRIPTION
The present disclosure relates to compounds of formula
The present invention relates to isoindolinone compounds of the formula I
##STR00001## in which A, X, R1b, R1c, R2a, R2b, R2c, R3, R4, R30, Y and Z are defined as indicated below. The isoindolinone compounds I are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity,
BACKGROUND INFORMATION
An estimated 1.1 billion adults worldwide are overweight or obese, one hundred thirty million of whom are adults in the United States. See, Haslam, D., Sattar, N., & Lean, M. (2006). Obesity--time to wake up. Bmj, 333(7569) 640-642; Flegal, K. M., Carroll, M. D., Ogden, C.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is National Phase application under 35 U.S.C. .sctn. 371 of International Application No. PCT/EP2015/057413, filed Apr. 2, 2015, which claims priority benefit to European Application No. 14305491.4, filed Apr. 4, 2014, the disclosures of each
The present invention relates to heterocyclic compounds of the formula I
##STR00001## in which R1a, R1b, R1c, R2a, R2b, R2c, R3, R4, R30, A, B, E, G, Y and Z are defined as indicated below. The fused heterocyclic compounds I are GPR119 modulators and useful for the prevention and/or treatment of
BACKGROUND INFORMATION
An estimated 1.1 billion adults worldwide are overweight or obese, one hundred thirty million of whom are adults in the United States. See, Haslam, D., Sattar, N., & Lean, M. (2006). Obesity--time to wake up. Bmj, 333(7569) 640-642; Flegal, K. M., Carroll, M. D., Ogden, C.
BACKGROUND
An estimated 1.1 billion adults worldwide are overweight or obese, one hundred thirty million of whom are adults in the United States. See, Haslam, Sattar, N., & Lean, M. (2006). Obesity--time to wake up. Bmj, 333(7569), 640-642; Flegal, K. M., Carroll, M. D., Ogden, C. L., &
FIELD OF THE INVENTION
The instant invention is concerned with inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type I enzyme, including pharmaceutically acceptable salts and prodrugs thereof, which are useful as therapeutic compounds, particularly in the treatment of non-insulin dependent
RELATED APPLICATIONS
This is a .sctn.371 of International Application No. PCT/JP2009/063632, with an international filing date of Jul. 31, 2009 (WO 2010/013798 A1, published Feb. 4, 2010), which is based on Japanese Patent Application No. 2008-198047, filed Jul. 31, 2008, the subject matter of which
FIELD OF THE INVENTION
The present invention relates to inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase Type I (11.beta.-HSD-1 or HSD-1), and methods of treatment using such compounds. The compounds are useful for the treatment of diabetes, such as non-insulin dependent type 2 diabetes